Moderna Q4 EPS $0.55 May No Be Comparable To $(0.97) Estimate, Sales $2.81B Beat $2.49B Estimate
Portfolio Pulse from Benzinga Newsdesk
Moderna (NASDAQ:MRNA) reported Q4 earnings of $0.55 per share, surpassing the consensus estimate of $(0.97) by 156.7%. However, this represents an 84.76% decrease from last year's earnings of $3.61 per share. Q4 sales were $2.81 billion, exceeding estimates of $2.49 billion by 12.89%, but marking a 44.71% decrease from the previous year's $5.08 billion.

February 22, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's Q4 earnings and sales surpassed estimates, with earnings of $0.55 per share and sales of $2.81 billion, despite significant year-over-year declines.
Moderna's earnings and sales beat not only demonstrates the company's ability to outperform market expectations but also highlights its resilience in a challenging year-over-year comparison. The significant beat on both earnings and sales estimates could positively influence investor sentiment in the short term, despite the noted decreases from the previous year's figures. The positive surprise in earnings, especially turning a profit against an expected loss, is a strong bullish signal for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100